Personalized pre-surgery treatment for HER2-negative early breast cancer
Part of Cancer clinical trials.
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have invasive breast cancer (not just abnormal cells).
- Your breast cancer tests negative for HER2 (a specific cancer marker).
- Your cancer is early stage, such as T2 or lymph node–positive (not stage IV).
- Your overall health is good enough to be active most of the time (ECOG 0–1).
- Your cancer is not inflammatory breast cancer.
- You do not have severe long-term (chronic) medical problems that could limit treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This study tests whether using a personalized approach to treatment after chemotherapy can improve outcomes for people with HER2-positive or triple-negative breast cancer. It aims to tailor further therapy based on how well the tumor responds initially.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
Hear when a new HER2-negative Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.